Core Viewpoint - The company, Morning Bio-Technology Group Co., Ltd., is actively engaging with investors to discuss its business development, market strategies, and future plans, indicating a focus on transparency and investor relations [1]. Group 1: Cottonseed Business - The chairman stated that last year's losses in the cottonseed business were primarily due to market fluctuations and operational issues, but the company has implemented strategies to lock in profits during processing, effectively controlling risks [3]. - The company has achieved normal production and delivery for the current quarter's cottonseed procurement and plans to enhance gross margins by increasing protein content and optimizing production management [3]. - Although the company withdrew its application for listing the cottonseed segment on the Beijing Stock Exchange due to market changes, it remains open to pursuing this business development in the future if suitable opportunities arise [3]. Group 2: Lutein Business - The company’s secretary noted that lutein prices are currently low but are expected to rise in the future, with the company leveraging its advantages in raw materials, such as self-built planting bases and improved breeding technology, to expand market share [3]. - Despite a decrease in raw material purchase prices affecting farmers' planting enthusiasm, the company believes that long-term base construction will gradually increase its market share in the lutein sector [3]. - The trend of natural colorants replacing synthetic ones presents significant opportunities for the industry, and the company plans to actively monitor market changes to seize these opportunities [3]. Group 3: Chili Business - The company highlighted that the price sensitivity of users to chili red pigment, a food additive, is low, with price changes mainly influenced by raw material costs [4]. - The company enjoys a significant cost advantage due to high processing yields compared to peers, and the domestic chili raw material advantage has led to an increase in market share in the chili pigment business [4]. - The company is advancing its planting base in Myanmar, which is ideal for marigold cultivation, to enhance its raw material supply capabilities [4]. Group 4: Future Outlook - The company will continue to focus on its core business by enhancing core competitiveness through technological innovation, market expansion, and industry chain integration [4]. - The company emphasizes the importance of closely monitoring market dynamics and policy changes to flexibly adjust strategic directions, ensuring stable business progress [4].

Core Viewpoint - The company reported a slight decline in revenue but a significant increase in net profit and earnings per share, indicating strong operational efficiency and profitability despite revenue challenges [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 1.716 billion yuan, a year-on-year decrease of 0.9% [1]. - The net profit attributable to shareholders was 109 million yuan, reflecting a year-on-year increase of 183.7% [1]. - Basic earnings per share (EPS) reached 0.2266 yuan, up 212.6% year-on-year [1]. Business Segment Analysis - The cottonseed business has returned to normal operations, while the plant extraction business has exceeded expectations [2]. - The plant extraction segment generated revenue of 867 million yuan, a year-on-year increase of 13.8%, with a gross margin improvement of 2.15 percentage points [2]. - The cottonseed segment reported revenue of 760 million yuan, a year-on-year decrease of 9.5%, with a gross margin of approximately 6.1% [2]. Market Strategy - The company adopted a strategy of "price for volume," leading to increased sales volume and revenue growth in various product lines [3]. - The price of chili red pigment significantly decreased, resulting in a revenue increase of approximately 7% due to volume elasticity [3]. - The company capitalized on domestic raw material cost advantages to expand into overseas markets, with chili extract sales doubling and contributing to a revenue increase of about 24% [3]. Long-term Outlook - The company is focused on long-term advantages, expanding overseas planting bases, and making breakthroughs in new businesses such as traditional Chinese medicine and health products [3]. - The company anticipates maintaining high growth rates in performance as major products return to a cyclical uptrend [3]. Investment Recommendation - The company is a leading player in the plant extract sector, with stable profitability in key products and a strong growth trajectory in market share [4]. - The ongoing construction of the Zambia plantation is expected to further reduce costs, and the health product business shows significant potential for growth [4]. - Projected EPS for 2025-2027 is 0.67, 0.83, and 1.00 yuan, with corresponding price-to-earnings ratios of 16.3X, 13.1X, and 10.9X, maintaining a "buy" rating [4].